Personalis, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Christopher M. Hall
- Full Time Employees
- 260
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- 6600 Dumbarton Circle Fremont CA United States 94555
- IPO Date
- Jun 20, 2019
- CIK
- 0001527753
- Website
- personalis.com
- Similar Companies
- Business
- Personalis, Inc. Personalis, Inc. (Nasdaq:PSNL) develops, markets and sells advanced cancer genomic tests and services to pharmaceutical, biopharmaceutical, diagnostics companies, universities, non-profits, government entities and patients in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for minimal residual disease detection, therapy response and recurrence monitoring in solid tumor cancers; ImmunoID NeXT, a tissue-based service combining whole exome and whole transcriptome sequencing with advanced analytics for multi-dimensional tumor and microenvironment analysis; NeXT Personal Dx and NeXT Dx for MRD detection and tumor profiling to guide therapy selection and clinical trials; whole exome and genome sequencing services for diagnostic inputs and population research initiatives; as well as proprietary ACE Technology for enhanced sequencing accuracy across difficult genomic regions. Personalis serves the precision oncology sector, focusing on biomarker discovery, personalized cancer immunotherapies, neoantigen prediction and translational research to support drug development and clinical trials. Founded in 2011 and headquartered in Fremont, California, the company recently expanded its collaboration with Tempus AI, Inc. through a $36 million equity investment in 2024 to accelerate commercialization of ultra-sensitive MRD testing for colorectal cancer; received a $50 million investment from Merck in December 2024, resulting in approximately 16.5% ownership, alongside a multi-year extension of its partnership with Moderna for the ImmunoID NeXT Platform in the V940/mRNA-4157 individualized neoantigen therapy program; and plans reimbursement submissions for NeXT Personal products to CMS in late 2024 or early 2025.
Company News
PSNL Securities Notice: Personalis, Inc. Shareholders Are Notified to Contact BFA Law About Its Pending Investigation into the $16.25 per Share Merger Deal
PSNL Stock Notification: Personalis, Inc. is being Investigated after the $16.25 per share Merger Deal Announced -- Investors are Alerted to Contact BFA Law
PSNL Stock Notification: Personalis, Inc. is being Investigated after the $16.25 per share Merger Deal Announced – Investors are Alerted to Contact BFA Law
Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026
Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test
Aaron Tachibana Sells 2,931 Shares of Personalis (NASDAQ:PSNL) Stock
Stephen Michael Moore Sells 2,068 Shares of Personalis (NASDAQ:PSNL) Stock
Richard Chen Sells 3,998 Shares of Personalis (NASDAQ:PSNL) Stock
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)
Personalis (NASDAQ:PSNL) CEO Christopher Hall Sells 7,459 Shares
Reviewing Personalis (NASDAQ:PSNL) and Mettler-Toledo International (NYSE:MTD)
Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders?
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
Personalis, Inc. $PSNL Shares Bought by Bank of America Corp DE
Personalis, Inc. (NASDAQ:PSNL) Given Consensus Recommendation of “Hold” by Brokerages
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
Personalis Reports Second Quarter Results and Recent Highlights
PSNL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Personalis to Tempus AI
Are BOW, UTZ, PSNL Obtaining Fair Deals for their Shareholders?
PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus